Learn More
This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isolates were identified. The identified species were C.(More)
In this study techniques were employed to induce exercising subjects to focus attention on themselves or on an external event. A total of 20 adult subjects (10 men and 10 women) were familiarized with a treadmill exercise protocol and then on two subsequent occasions performed submaximal exercise followed by a run to exhaustion under attentional conditions(More)
The effects of different types of music on heart rate (HR), rating of perceived exertion (RPE), and time to exhaustion during treadmill work were determined on 24 volunteer college students (Ss). The Ss participated in three randomly assigned multistaged treadmill walk/run to exhaustion while wearing a head-set. The three treatments were: loud, fast,(More)
It has been suggested in the lay literature that static stretching and/or warm-up will prevent the occurrence of Delayed-Onset Muscle Soreness (DOMS). The primary purpose of this study was to determine the effects of static stretching and/or warm-up on the level of pain associated with DOMS. Sixty-two healthy male and female volunteers were randomly(More)
Candida osteomyelitis is associated with significant morbidity; however, data on the management of Candida osteomyelitis are limited. The Prospective Antifungal Therapy (PATH) Alliance® registry is a comprehensive, multicenter, prospective, observational registry that collected data on patients with invasive fungal infections between 2004 and 2008. The aim(More)
OBJECTIVE To explore any differences in efficacy and safety outcomes between European (EU) (n = 684) and North American (NA) (n = 395) patients in the AFFIRM trial (NCT00974311). PATIENTS AND METHODS Phase III, double-blind, placebo-controlled, multinational AFFIRM trial in men with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.(More)
  • 1